Tag

Gilead Sciences

All articles tagged with #gilead sciences

business4 days ago•1 min saved

Gilead to Acquire Arcellx in $7.8 Billion CAR-T Focused Deal

Gilead will buy Arcellx for $7.8 billion in cash, valuing Arcellx at $115 per share with a 79% premium and expanding their joint development of the anti-cancer CAR-T therapy anito-cel for multiple myeloma. The deal follows Arcellx's collaboration with Kite Pharma, and the FDA is reviewing anito-cel with a decision expected by year-end. The acquisition is expected to be EPS-accretive in 2028 and includes a $5 per share milestone payment if cumulative global net sales of anito-cel reach $6 billion through 2029.

via CNBC|

#arcellx #biotech #business

health3 months ago•1 min saved

Expert predicts Gilead's $25 HIV prevention shot could help eradicate the disease in the U.S.

Gilead Sciences' new HIV prevention shot, Yeztugo, shows high efficacy but faces challenges in adoption due to its high $28,000 price tag, with CVS Caremark declining to include it in its formulary despite other insurers moving forward, raising concerns about affordability and disease eradication efforts in the U.S.

via statnews.com|

#gilead-sciences #health #hiv-prevention

healthcare4 months ago•3 min saved

AstraZeneca and Gilead Compete for Leadership in Triple-Negative Breast Cancer Treatments

Major pharmaceutical companies Gilead, AstraZeneca, and Roche reported promising new study results for cancer treatments, particularly in breast cancer, leading to stock price increases for Gilead and AstraZeneca, while Roche's shares declined slightly. The studies highlight advancements in drug efficacy and potential growth in the cancer drug market, with implications for future sales and industry competition.

via TipRanks|

#astrazeneca #breast-cancer #cancer

health5 months ago•2 min saved

PEPFAR and Gilead Collaborate to Expand HIV Prevention with Breakthrough Drug

The U.S. Department of State announced a PEPFAR initiative to bring Gilead Sciences' breakthrough HIV drug lenacapavir to high-burden countries, aiming to reach up to 2 million people by 2028. The twice-yearly injectable medication, which has shown over 99% effectiveness in clinical trials, will be distributed with the support of the U.S. government and the Global Fund, at no profit from Gilead, to help prevent mother-to-child transmission and reduce HIV infections globally.

via U.S. Department of State (.gov)|

#gilead-sciences #global-health #health

health8 months ago•2 min saved

FDA Approves Long-Lasting HIV Prevention Injection

The FDA has approved lenacapavir, a long-acting injectable HIV prevention drug that is nearly 100% effective with just two doses per year, representing a significant advancement in HIV prevention, though its high cost may limit access in low-income regions.

via WIRED|

#fda-approval #gilead-sciences #health

health8 months ago•3 min saved

FDA Approves Gilead's Long-Acting HIV Prevention Injection

The FDA has approved Gilead Sciences' twice-yearly injection, lenacapavir, for HIV prevention, showing over 99.9% effectiveness in clinical trials, which could be a major breakthrough in HIV prevention efforts, though concerns about high costs remain.

via ScienceAlert|

#fda-approval #gilead-sciences #health

health8 months ago•3 min saved

FDA Approves Long-Acting HIV Prevention Drug Lenacapavir

The FDA has approved Gilead Sciences' lenacapavir as a twice-yearly PrEP drug to prevent HIV, showing high effectiveness in clinical trials, but concerns remain about its high cost and accessibility.

via Gizmodo|

#fda-approval #gilead-sciences #health

health8 months ago•8 min saved

FDA Approves Biannual HIV Prevention Shot for Enhanced Protection

The FDA has approved Yeztugo, a long-acting HIV prevention drug by Gilead Sciences, which is injected twice a year and shows high efficacy in preventing HIV transmission, especially among high-risk populations. Despite its potential, challenges such as high cost, insurance coverage issues, and political funding cuts could hinder its widespread use and impact on reducing HIV rates in the US.

via NBC News|

#gilead-sciences #health #hiv-prevention

health9 months ago•4 min saved

Gilead Advances HIV Prevention in Low-Income Countries Amid Funding Concerns

Gilead Sciences plans to supply its HIV prevention injection lenacapavir to low-income countries if approved by the FDA, despite funding uncertainties due to U.S. aid cuts, with potential rollout in 2026 to help end the HIV epidemic globally.

via Reuters|

#funding-uncertainty #gilead-sciences #health

health1 year ago•1 min saved

Report: Unsupported Drug Price Hikes Cost U.S. $815M in 2023

In 2023, drugmakers increased prices on five widely used drugs without new clinical evidence, costing U.S. patients and insurers an additional $815 million, according to a report by the Institute for Clinical and Economic Review. The largest spending increase was for Biktarvy, an HIV treatment by Gilead Sciences, which saw a 5.9% wholesale price hike, resulting in $359 million more in spending. Gilead claims some study data were overlooked or rejected, challenging the report's findings.

via STAT|

#drug-pricing #gilead-sciences #health

stock-market1 year ago•3 min saved

"Key Insights for Today's Stock Market Opening"

Nvidia shares are falling on "triple witching" day, Gilead Sciences is rising after positive HIV drug trial results, Sarepta Therapeutics soars on expanded FDA approval for its gene therapy, Chipotle is in focus ahead of its 50-for-1 stock split, and CarMax gains despite missing quarterly forecasts.

via Yahoo Finance|

#carmax #chipotle-mexican-grill #gilead-sciences

stock-market1 year ago•3 min saved

"Key Insights for Today's Stock Market Opening"

Nvidia shares are falling on "triple witching" day, Gilead Sciences is gaining on positive HIV drug trial results, Sarepta Therapeutics soars after expanded FDA approval for its gene therapy, Chipotle is in focus ahead of a 50-for-1 stock split, and CarMax shares rise despite missing quarterly forecasts. U.S. stock futures are down following Nvidia's decline.

via Investopedia|

#carmax #chipotle-mexican-grill #gilead-sciences

stock-market-update1 year ago•3 min saved

Triple Witching Friday: Key Market Movers and What to Know

Investors should note that the S&P 500 and Nasdaq are on track for a winning week despite a slight pullback on Thursday. AI company Anthropic launched its new model, Claude 3.5 Sonnet. Gilead's experimental HIV shot showed 100% effectiveness in a late-stage trial. Trump Media's stock fell 15% amid high trading volume. Amazon is replacing plastic air pillows with paper fillers in its packaging.

via CNBC|

#ai-technology #amazon #gilead-sciences

health1 year ago•12 min saved

Gilead's HIV Prevention Shot Achieves 100% Efficacy in Trials

Gilead Sciences announced that its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy in preventing HIV infections in cisgender women during the Phase 3 PURPOSE 1 trial. The independent Data Monitoring Committee recommended stopping the blinded phase of the trial and offering open-label lenacapavir to all participants. This marks the first Phase 3 HIV prevention trial to show zero infections, highlighting lenacapavir's potential as a significant new tool for HIV prevention.

via Gilead Sciences|

#clinical-trials #gilead-sciences #health

health1 year ago•14 min saved

Gilead Updates on Phase 3 TROPiCS-04 Study Progress

Gilead Sciences announced that the Phase 3 TROPiCS-04 study of Trodelvy in metastatic urothelial cancer did not meet its primary endpoint of overall survival. While some numerical improvements were observed, there were higher deaths due to adverse events with Trodelvy. Gilead will further investigate and discuss the results with the FDA. Trodelvy remains approved for other indications, and Gilead continues to explore its use in various cancers.

via Gilead Sciences|

#clinical-trials #gilead-sciences #health